MyFinsight
Home
Blog
About
Marketable securities
$201,434K
(64.11%↑ Y/Y)
Cash and cash
equivalents
$49,326K
(-15.08%↓ Y/Y)
Prepaid expenses and
other current assets
$5,578K
(-6.43%↓ Y/Y)
Total current assets
$256,338K
(37.16%↑ Y/Y)
Operating lease
right-of-use assets
$4,541K
(-21.87%↓ Y/Y)
Deposits and other assets
$2,500K
Restricted cash
equivalents
$986K
(-32.05%↓ Y/Y)
Property and equipment,
net
$199K
(-55.28%↓ Y/Y)
Total assets
$264,564K
(35.95%↑ Y/Y)
Total liabilities and
stockholders' equity
$264,564K
(35.95%↑ Y/Y)
Total stockholders'
equity
$239,167K
(42.47%↑ Y/Y)
Total liabilities
$25,397K
(-4.95%↓ Y/Y)
Accumulated deficit
-$836,134K
(-22.23%↓ Y/Y)
Additional paid-in capital
$1,075,271K
(26.30%↑ Y/Y)
Total current
liabilities
$21,150K
(-1.28%↓ Y/Y)
Operating lease
liabilities, net of current...
$4,247K
(-19.82%↓ Y/Y)
Accumulated other
comprehensive income
$19K
(-96.55%↓ Y/Y)
Common stock, 0.0001
par value...
$11K
(22.22%↑ Y/Y)
Accrued expenses
$14,609K
(-16.35%↓ Y/Y)
Accounts payable
$5,533K
(67.97%↑ Y/Y)
Operating lease
liabilities, current portion
$1,008K
(51.58%↑ Y/Y)
Back
Back
Balance Sheet
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)
source: myfinsight.com